Accelerate research, support patients and families affected by fibrolamellar carcinoma, and drive discovery of effective treatments.
The Fibrolamellar Cancer Foundation centers its giving on fibrolamellar carcinoma research, with grantmaking that moves from disease-model development and biospecimen sharing to clinical-trial patient support. Its recent awards show a strong emphasis on scientific work that can advance treatment discovery, including a $2,404,179 grant to Dracen Pharmaceuticals Inc in San Diego and a $540,000 grant to the University of Washington in Seattle. The foundation also funds infrastructure that researchers use across projects, such as biospecimen resources, data sharing, and model validation programs tied to FLC. The grant list points to a research-oriented funder that supports both institutions and specialized biotech collaborators. University settings appear repeatedly, alongside cancer centers and laboratories, suggesting a mix of basic, translational, and applied work. The foundation’s active programs also include support for patient assistance during clinical trial participation, linking its research agenda to the lived experience of people affected by fibrolamellar carcinoma. Across the record, its priorities stay tightly focused on one disease area rather than a broad health portfolio.
In biomedical research, the foundation backed X-chem Inc in Waltham, Massachusetts with $400,000 in 2025 and Seven Bridges Genomics Inc in Charlestown, Massachusetts with $324,000 in 2025, pointing to interest in discovery platforms and data-enabled research. For translational and preclinical work, it gave $388,554 to Cornell University College of Veterinary Medicine in Ithaca, New York in 2023 and $317,914 to Children’s Hospital Medical Center in Cincinnati, Ohio in 2024. Its biospecimen and resource-sharing priorities are reflected in grants to Massachusetts General Hospital Cancer Center in Boston, including $199,997 in 2023 and $199,996 in 2025. The foundation also supported disease-model work through Stanford University in Redwood City, California with $49,500 in 2024. These awards align with programs for disease models, biospecimen access, and research resources for fibrolamellar carcinoma.
Typical grant size clusters around $49,999 at the 25th percentile, a median of $165,000, and $235,000 at the 75th percentile. The recent list includes both large, project-level awards and smaller grants under $50,000, indicating a layered approach to research support. Several recipients appear in multiple years, including the University of Washington, St Jude Children’s Research Hospital, Johns Hopkins, Massachusetts General Hospital Cancer Center, Fred Hutchinson Cancer Center, Dana-Farber Cancer Institute, Cornell University College of Veterinary Medicine, and the University of Wisconsin. The foundation operates as a private grantmaker focused on scientific and technical investigation, and its active programs show both unsolicited and non-unsolicited mechanisms across different offerings.
$1.4M
$10.2M
$3.4M
$2.9M
Most grants fall between $50K and $235K, with a median of $165K.
25th Percentile
$50K
Median
$165K
75th Percentile
$235K
About 0% of grants go to recipients in MA.
KURT LOSERT
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeRegístrate gratis para ver qué tan bien se adapta tu organización sin fines de lucro a este financiador, obtener un pitch generado por IA y descubrir fundaciones similares.
All recent grants in the file went to U.S. recipients, and California is the top state by grant count. Seattle appears repeatedly through the University of Washington and Fred Hutchinson Cancer Center, while Boston shows up through Massachusetts General Hospital Cancer Center, Boston Children’s Hospital, and Dana-Farber Cancer Institute. Other recipient cities include Ithaca, Baltimore, Cincinnati, San Diego, Charlestown, and La Jolla. The grant map is national, with no recipients in Connecticut among the recent awards.
Its core focus is fibrolamellar carcinoma research, especially biomedical research, clinical trials, biospecimen collection and sharing, disease model development, and bioinformatics and data sharing. The foundation also includes patient support and resources in its program list.
The grant-size distribution centers at $49,999 at the 25th percentile, a median of $165,000, and $235,000 at the 75th percentile. The recent record also includes a much larger $2,404,179 award and several grants under $50,000.
The recent grants list shows 26 grants to U.S. recipients, or 100.0% of the sample provided. The active program descriptions include global or worldwide access for some research resources, but the recent grant distribution shown here is entirely U.S.-based.
Several recipients appear more than once in the recent grants list, including the University of Washington, St Jude Children’s Research Hospital, Johns Hopkins, Massachusetts General Hospital Cancer Center, Fred Hutchinson Cancer Center, Dana-Farber Cancer Institute, Cornell University College of Veterinary Medicine, and the University of Wisconsin.
It also runs resource and support programs, including disease-model resources, clinical-trial patient assistance, FCF biospecimen support, FCF biobank distribution, and a research-collaboration travel fund. Those programs suggest a mix of direct funding and infrastructure support for FLC research.
2025
Source: IRS Form 990-PF, fiscal year 2025.
Financiamiento actual y próximo de Fibrolamellar Cancer Foundation al que tu organización sin fines de lucro podría postularse.
¿Quién puede postularse? Applicants must be employed by an institution engaged in health-related research. Research must focus specifically on FLC and aim to advance understanding, diagnosis, epidemiology, or treatment. Collaboration and open sourcing are required.
Fecha límite: March 1, July 1, and November 1 each year
¿Quién puede postularse? Awards are offered to laboratories or organizations that make patient-derived xenografts (PDX) or stable cell/organoid lines of human FLC available to the research community.
Fecha límite: Not specified on the page.
¿Quién puede postularse? Authorized researchers requesting samples and/or clinical data for FLC-specific research.
Haz seguimiento de estas fechas límite, recibe recordatorios y descubre qué tan bien encaja tu organización — gratis con una cuenta de Kindora.
Crea una cuenta gratisLas fechas límite y los requisitos de elegibilidad son un resumen de fuentes públicas y pueden cambiar — confirma siempre los detalles en la página oficial de solicitud del financiador antes de postularte.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| X-CHEM INC | WALTHAM, MA | $400,000 | 2025 | SCIENTIFIC RESEARCH |
| SEVEN BRIDGES GENOMICS INC | CHARLESTOWN, MA | $324,000 | 2025 | SCIENTIFIC RESEARCH |
| UNIVERSITY OF WASHINGTON | SEATTLE, WA | $200,000 | 2025 | SCIENTIFIC RESEARCH |
| MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER | BOSTON, MA | $199,996 | 2025 | SCIENTIFIC RESEARCH |
| UNIVERSITY OF WISCONSIN | MADISON, MI | $138,212 | 2025 | SCIENTIFIC RESEARCH |
| FRED HUTCHINSON CANCER CENTER | SEATTLE, WA | $125,000 | 2025 | SCIENTIFIC RESEARCH |
| DANA-FARBER CANCER INSTITUTE | BOSTON, MA | $15,040 | 2025 | SCIENTIFIC RESEARCH |
| DRACEN PHARMACEUTICALS INC | SAN DIEGO, CA | $2,404,179 | 2024 | SCIENTIFIC RESEARCH |
| UNIVERSITY OF WASHINGTON | SEATTLE, WA | $540,000 | 2024 | SCIENTIFIC RESEARCH |
| CHILDREN'S HOSPITAL MEDICAL CENTER | CINCINNATI, OH | $317,914 | 2024 | SCIENTIFIC RESEARCH |
| ST JUDE CHILDREN'S RESEARCH HOSPITAL | MEPHIS, TN | $200,000 | 2024 | SCIENTIFIC RESEARCH |
| JOHNS HOPKINS | BALTIMORE, MD | $200,000 | 2024 | SCIENTIFIC RESEARCH |
| CORNELL UNIVERSITY COLLEGE OF VETERINARY MEDICINE | ITHACA, NY | $128,554 | 2024 | SCIENTIFIC RESEARCH |
| FRED HUTCHINSON CANCER CENTER | SEATTLE, WA | $125,000 | 2024 | SCIENTIFIC RESEARCH |
| STANFORD UNIVERSITY | REDWOOD CITY, CA | $49,500 | 2024 | SCIENTIFIC RESEARCH |
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO | SAN FRANCISCO, CA | $49,433 | 2024 | SCIENTIFIC RESEARCH |
| DANA-FARBER CANCER INSTITUTE | BOSTON, MA | $34,374 | 2024 | SCIENTIFIC RESEARCH |
| UNIVERSITY OF WISCONSIN | MADISON, MI | $25,000 | 2024 | SCIENTIFIC RESEARCH |
| CORNELL UNIVERSITY COLLEGE OF VETERINARY MEDICINE | ITHACA, NY | $388,554 | 2023 | SCIENTIFIC RESEARCH |
| UIVERSITY OF WASHINGTON | SEATTLE, WA | $270,000 | 2023 | SCIENTIFIC RESEARCH |
| ST JUDE CHILDREN'S RESEARCH HOSPITAL | MEPHIS, TN | $200,000 | 2023 | SCIENTIFIC RESEARCH |
| MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER | BOSTON, MA | $199,997 | 2023 | SCIENTIFIC RESEARCH |
| UNIVERSITY OF CALIFORNIA SAN DIEGO | LA JOLLA, CA | $165,000 | 2023 | SCIENTIFIC RESEARCH |
| BOSTON CHILDREN'S HOSPITAL | BOSTON, MA | $49,999 | 2023 | SCIENTIFIC RESEARCH |
| UNIVERSITY OF WISCONSIN | MADISON, MI | $49,999 | 2023 | SCIENTIFIC RESEARCH |
| JOHNS HOPKINS | BALTIMORE, MD | $49,999 | 2023 | SCIENTIFIC RESEARCH |
X-CHEM INC
$400,000SCIENTIFIC RESEARCH
SEVEN BRIDGES GENOMICS INC
$324,000SCIENTIFIC RESEARCH
UNIVERSITY OF WASHINGTON
$200,000SCIENTIFIC RESEARCH
MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER
$199,996SCIENTIFIC RESEARCH
UNIVERSITY OF WISCONSIN
$138,212SCIENTIFIC RESEARCH
SCIENTIFIC RESEARCH
DRACEN PHARMACEUTICALS INC
$2,404,179SCIENTIFIC RESEARCH
UNIVERSITY OF WASHINGTON
$540,000SCIENTIFIC RESEARCH
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO
$49,433SCIENTIFIC RESEARCH
UNIVERSITY OF WISCONSIN
$25,000SCIENTIFIC RESEARCH
UIVERSITY OF WASHINGTON
$270,000SCIENTIFIC RESEARCH
MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER
$199,997SCIENTIFIC RESEARCH
UNIVERSITY OF CALIFORNIA SAN DIEGO
$165,000SCIENTIFIC RESEARCH
UNIVERSITY OF WISCONSIN
$49,999SCIENTIFIC RESEARCH
